GSK Partners With Myogen Ahead Of Ambrisentan Launch

GlaxoSmithKline will commercialize Myogen’s selective endothelin receptor antagonist for pulmonary arterial hypertension outside the U.S. following approval; Myogen will take over marketing of GSK’s Flolan in the U.S.